Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HERVCOV

Financiado

Cerrado

SARS CoV 2 induced activation of pathogenic endogenous retrovirus envelope HERV...

SARS CoV 2 induced activation of pathogenic endogenous retrovirus envelope HERV W towards personalized treatment of COVID 19 patients Severe COVID-19 disease and the high frequency of its long-term complications are now a major health problem worldwide. Due to the significant heterogeneity of COVID-19 disease profiles, biomarkers that allow either the identifica... ver más

30/06/2027

Líder desconocido

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto Líder desconocido

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-06-02

HORIZON-HLTH-2021-DISEASE-04-07: Personalised medicine and infectiou... Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one o...

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIVERSITA DEGLI STUDI DI RO...

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 60 meses Fecha Inicio: 2022-06-02
Fecha Fin: 2027-06-30

Líder del proyecto Líder desconocido

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Severe COVID-19 disease and the high frequency of its long-term complications are now a major health problem worldwide. Due to the significant heterogeneity of COVID-19 disease profiles, biomarkers that allow either the identification of patients at high risk for developing severe forms of COVID-19 and its long-term complications, or guide personalized treatment options, are scarce. The HERVCOV project aims to analyze the role of human endogenous retroviruses (HERVs), known for their high pro-inflammatory potential, in the immunopathogenesis of COVID-19 and to identify and evaluate a set of biomarkers which will be important for the diagnosis, prognosis and follow-up of COVID-19 patients and their prioritization for targeted therapy. Recent data from the consortium has demonstrated that HERV-W envelope protein is highly expressed in lymphocytes of COVID-19 patients and correlates with inflammatory markers and respiratory outcome of the disease, strongly suggesting the role of HERVs in COVID-19 pathogenesis. The project aims to assess the biological pathways and functions that underlie the association of HERV expression and activation with severe COVID-19 forms and related complications. Biomarkers based on HERV pathogenic protein activation, SARS-CoV-2-specific immune responses, cytokine production and mandatory medical blood analyses for COVID-19 clinical monitoring will be studied in samples from different forms of COVID-19: acute, post- neuro- and long-COVID patients. Parameters will be determined that predict the clinical course of the disease and aggravation of SARS-CoV-2-induced symptoms and allow potential clustering of different bio-clinical profiles of COVID-19 patients. Diagnostic and prognostic panel(s) ?translated? from our fundamental research and subsequent evaluations of HERV-associated biomarkers will be assessed to define novel indicators in precision medicine-based therapeutic strategies, leading to individualized medical treatment in COVID-19.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores